Skip to main content
Translating Science

Transforming Lives

Extending life’s moments for people living with rare diseases
Owen
Phenylketonuria, United States
Owen - PKU - North America

Innovation, fueled by science and a passion for patients

PTC is an established global biopharmaceutical company that delivers transformative therapies for people living with rare diseases. For 25 years, we have been harnessing our scientific platforms to create new therapies that address the underlying cause of the disease and deliver on our promise to create more moments for those who count on us.

Pioneers in Modulating Gene and Protein Expression

  1. Nonsense Suppression

    Bypassing translation mutations to enable protein production
  2. Splicing

    Modulating splicing to control protein production
  3. Bio-e

    Targeting mitochondrial pathologies to treat CNS diseases and cancer
  4. Gene Therapy

    Targeted genetic therapies to treat rare CNS disorders
The PTC Pipeline

Challenging what's possible

Harnessing groundbreaking science for patients has led to many firsts – the first approved treatment for Duchenne in the world, the first approved gene therapy directly infused into the brain, and the first approved small molecule splicing modifier. Our innovative pipeline continues to expand as we discover and develop treatments using the newest technologies available.

Join Our Team

We love what we do

PTC employees are working to change patients’ lives every single day.

We are motivated by our patients and the drive for them to have more moments with their families, made possible in part by our research and therapies.
If you’re looking to take on rewarding work with inspiring colleagues, come grow with us.

Careers at PTC
The Latest on PTC

Making headlines

See all articles
  • Press Release

    NICE Recommends Reimbursement for Translarna™

    PTC Therapeutics, Inc. today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Evaluation Document recommending Translarna™ (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales.
    READ MORE
  • Press Release

    PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

    PTC Therapeutics, Inc. today announced the launch of the ninth annual STRIVE™ awards program. Through this program, PTC awards grants to patient advocacy organizations who are committed to developing initiatives that address the needs of the Duchenne Muscular Dystrophy (Duchenne) community.
    READ MORE
  • Presentation

    PTC presents at the 41st Annual J.P. Morgan Healthcare Conference

    PTC Therapeutics, Inc. presented at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023. Click here for the presentation.
    READ MORE
See all articles
hcp-icon
Resources For
Healthcare Providers

PTC works closely with healthcare providers to support their needs

patient-cg-icon
Resources For
Patients & Caregivers

Support for the PTC patient, family, and caregiver community

investors-icon
Information for
Investors

Explore our investor relations section and sign up for alerts on important PTC developments